Skip to main content
. 2023 Mar 30;90:104543. doi: 10.1016/j.ebiom.2023.104543

Fig. 2.

Fig. 2

Association of genetically proxied drug targets with risk of non-alcoholic fatty liver disease. Forest plot of the association between a 1-mmol/L (LDL-C, 38.7 mg/dL; TG, 88.9 mg/dL) change in the lipid levels of nine lipid-lowering drug targets with NAFLD risk in the discovery dataset (A), and NAFLD risk in the replication dataset (B). Data are represented as odds ratios (ORs) with 95% confidence intervals (error bars). An OR of <1.00 suggests a decreased risk of disease associated with lipid-lowering drug treatment. Associations are significant after correcting for multiple testing (9 genes, p < 0.05/9). Abbreviations: LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; SNP, single-nucleotide polymorphisms; HMGCR, HMG-CoA reductase; NPC1L1, Niemann-Pick C1-like protein 1; PCSK9, proprotein convertase subtilisin/kexin type 9; APOB, Apolipoprotein B-100; ABCG5, ATP Binding Cassette Subfamily G Member 5; ABCG8, ATP Binding Cassette Subfamily G Member 8; LDLR, LDL Receptor; ANGPTL3, angiopoietin-like 3; APOC3, Apolipoprotein C-III; LPL, lipoprotein lipase.